ArticleAging and disease2025
Bone Regeneration Enhanced by Quercetin-Capped Selenium Nanoparticles via miR206/Connexin43, WNT, and BMP signaling pathways.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
- Reconstructing the Periosteal Niche with Regenerated Cellulose Nanofibers for Endogenous Bone Regeneration.Journal of functional biomaterials · 2026Article
- Advanced herbal self-assembled nanoplatforms: targeted, stimuli-responsive, and precision therapeutics for human diseases.Journal of nanobiotechnology · 2026Review
- Mechanistic Insights Into the Estrogen-Like Effects of Selenium-Enriched Armillaria on Anti-Osteoporosis in Ovariectomized Rats.Biological trace element research · 2026Article
- Quercetin-loaded composite materials for bone regeneration: a review of carriers, controlled release, and mechanistic advances.Stem cell research & therapy · 2026Review
- Innovative synergy of bone xenograft and quercetin in the alveolar bone socket: Histological and immunohistochemical assessment of healing.Regenerative therapy · 2026Article
- Quercetin in bone regeneration: optimization of drug delivery system and study of its synergistic mechanism with bone tissue engineering.Frontiers in pharmacology · 2026Review
- A zingiberene-selenium nanoparticle formulation modulates oxidative, inflammatory, and osteogenic responses during femoral fracture healing in rats.Frontiers in veterinary science · 2026Article
- Phenolic-derived compounds in osteoporosis-Mechanisms, clinical evidence, and drug delivery: A review.Biomolecules & biomedicine · 2025Review
- Genomic structural equation modeling decodes skeletal aging: novel loci discovery and multisystem genetic crosstalk.Journal of translational medicine · 2025Article
- Polyphenols and Bone Health: A Comprehensive Review of Their Role in Osteoporosis Prevention and Treatment.Molecules (Basel, Switzerland) · 2025Review
- The Role of Senolytics in Osteoporosis.Biomolecules · 2025Review
- Selenium-containing nanoparticles and bone related disorders: from synthesis, bone metabolism to disease therapy.Frontiers in endocrinology · 2025Review
- PBVHx-based microspheres for controlled BMP2 release and enhanced bone regeneration in a disuse osteoporosis mouse model.Biomaterials translational · 2025Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related alterations in the skeletal system are linked to decreased bone mass, a reduction in bone strength and density, and an increased risk of fractures and osteoporosis. Therapeutics are desired to stimulate bone regeneration and restore imbalance in the bone remodeling process. Quercetin (Qu), a naturally occurring flavonoid, induces osteogenesis; however, its solubility, stability, and bioavailability limit its therapeutic use. Nanoformulation can improve the physical properties of Qu and enhance its bioactivity and bioavailability. Further, localized delivery of Qu nanoformulations at the site of bone defects could ensure high local concentration, augmenting its osteogenic properties. Thus, this study aims to synthesize selenium nanoparticles-based Qu nanoformulation (Qu-SeNPs) and evaluate their osteogenic stimulation ability along with localized bone regeneration ability. Here, the spontaneously synthesized Qu-SeNPs showed uniform size distribution and rough flower-shaped morphology. The confocal images indicate improved cellular uptake and even cellular distribution of Qu-SeNPs in osteoblasts, resulting in increased osteogenic activity as indicated by enhanced expression of early and late osteoprogenitor differentiation markers. Qu-SeNPs also decreased osteoblasts' RANKL/OPG ratio and inhibited osteoclast formation. Mechanistically, Qu-SeNPs activate critical signaling pathways, including WNT and BMP, and utilize the miR-206/Connexin43 pathway to enhance osteogenesis. In vivo, experiments utilizing a drill-hole bone defect model in mice indicate that hydrogel-mediated localized delivery of Qu-SeNPs significantly accelerates bone defect healing. Thus, well-characterized and mechanistic, detailed synthesized Qu-SeNPs can restore bone remodeling, and Qu-SeNPs embedded in hydrogels may improve Qu cellular uptake and bioavailability in clinical settings, enabling innovative orthopedic and regenerative therapies for bone loss/defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.